Amendments to the Specification

On page 34 of the specification, beginning on line 2 through line 21, please replace the following paragraph as follows:

To improve the expression of CAB1.10 protein, a combinatorial consensus mutagenesis CCM approach as described before (see U.S. Patent Application No. 10/688,255, filed October 16, 2003 ~~Attorney Docket Number 816P~~, which is incorporated by reference in its entirety, including any drawings) was pursued by targeting 35 amino acid residues in the frame work regions of vL and vH domains using plasmid pHR03.1 as a template. These 35 residues (14 positions in vH and 21 positions in vL) were identified as being significantly different (<10% abundance) compared to a typical human antibody sequence. Using a modified version of Multi-site Quikchange Mutagenesis (Stratagene, CA) protocol as described before (see U.S. Patent Application No. 10/688,255, filed October 16, 2003 ~~Attorney Docket Number 816P~~, which is incorporated by reference herein, including any drawings), CCM libraries HR12 and HR14 with combined primer concentrations of 2 uM and 0.4 uM, respectively, were constructed employing 35 phosphorylated primers as shown in table 1. After mutagenesis and DpnI digestion, 2.5 ul out of 25 ul PCR reaction mix was transformed into E. coli TOP10F' cells followed by selection on agar plates containing Luria-Bertani medium and 5 ppm chloramphenicol (cmp) and 0.1 ppm cephotaxim (CTX). 100 clones from library HR12 and 200 clones from library HR14 were initially screened for improved expression in 96-well microtiter plates as described below resulting in the selection of clone HR14.8. Sequencing of this clone revealed that it recruited A12S and R72G mutations in the vL region of the scFv fragment. Complete sequencing of the entire fusion gene of clone HR14.8 revealed no additional mutations elsewhere in the gene. This clone HR14.8 (encoded and was named) the CAB1.11 molecule.